The Lipidomic Signature of Glioblastoma: A Promising Frontier in Cancer Research

Cancers (Basel). 2024 Mar 8;16(6):1089. doi: 10.3390/cancers16061089.

Abstract

Glioblastoma is the most aggressive primary brain malignancy in adults, and has a survival duration of approximately 15 months. First line treatment involves surgical resection, chemotherapy, and radiation, but despite the multi-pronged approach and advances in cancer research, glioblastoma remains devastating with a high mortality rate. Lipidomics is an emerging discipline that studies lipid pathways and characteristics, and is a promising field to understand biochemical mechanisms. In glioblastoma, disrupted lipid homeostasis has been reported in the literature. A thorough understanding of serum lipidomics may offer ways to better understand glioblastoma biomarkers, prognosis, and treatment options. Here, we review the literature, offering future directions for lipidomics research in glioblastomas.

Keywords: brain cancer; glioblastoma; lipidomics.

Publication types

  • Review

Grants and funding

Orwa Aboud is supported in part by The UC Davis Paul Calabresi Career Development Award for Clinical Oncology as funded by the National Cancer Institute, National Institutes of Health through grant #2K12CA138464-11. Orwa Aboud has served on advisory board for Servier.